TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Upstream Bio, Inc. ( (UPB) ) has provided an announcement.
On September 2, 2025, Upstream Bio announced positive results from the Phase 2 VIBRANT trial for verekitug in treating chronic rhinosinusitis with nasal polyps (CRSwNP). The trial demonstrated significant improvements in nasal polyp and congestion scores, with a favorable safety profile, suggesting potential advancements in CRSwNP treatment. The results may also indicate verekitug’s utility in other respiratory diseases, such as severe asthma, highlighting its potential to transform care in multiple indications.
The most recent analyst rating on (UPB) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on Upstream Bio, Inc. stock, see the UPB Stock Forecast page.
Spark’s Take on UPB Stock
According to Spark, TipRanks’ AI Analyst, UPB is a Neutral.
Upstream Bio, Inc. receives a moderate stock score of 54, primarily driven by its strong equity position mitigating financial risks, despite significant operational and cash flow challenges. Technical analysis shows positive momentum but warns of potential corrections due to overbought conditions. The absence of valuation metrics adds uncertainty, highlighting the need for improved financial performance.
To see Spark’s full report on UPB stock, click here.
More about Upstream Bio, Inc.
Upstream Bio, Inc. is a clinical-stage company focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders. The company is known for its work on verekitug, a monoclonal antibody targeting the TSLP receptor, which is currently being evaluated in multiple clinical trials.
Average Trading Volume: 454,607
Technical Sentiment Signal: Strong Buy
Current Market Cap: $923.5M
For detailed information about UPB stock, go to TipRanks’ Stock Analysis page.